| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Ipflufenoquin targets dihydroorotate dehydrogenase (DHODH), an enzyme involved in the de novo biosynthesis of pyrimidine nucleotides. DHODH catalyzes the conversion of dihydroorotate to orotate in the RNA biosynthetic pathway. By inhibiting DHODH, the compound disrupts nucleotide synthesis, thereby affecting RNA biosynthesis and inhibiting fungal growth. FRAC has classified it as a DHODH inhibitor, group code 52.
|
|---|---|
| ln Vitro |
In vitro, Ipflufenoquin demonstrates potent inhibitory activity against a wide range of plant pathogenic fungi. It shows excellent efficacy against diseases such as scab (Venturia spp.), Alternaria leaf spot, gray mold (Botrytis spp.), anthracnose, Sclerotinia rot, and rice blast. The compound exhibits no cross-resistance with conventional fungicides such as strobilurins, benzimidazoles, triazoles, or SDHI fungicides. Its broad-spectrum activity makes it valuable for disease management in various crops.
|
| ln Vivo |
In vivo, Ipflufenoquin provides effective disease control in agricultural crops including potatoes, apples, pears, rice, tomatoes, wheat, barley, cucumbers, grapes, strawberries, and tobacco. It is effective against diseases caused by Oomycetes, Ascomycetes, Deuteromycetes, and Basidiomycetes. The compound demonstrates efficacy against fungal pathogens that have developed resistance to existing agents. It is also effective against bacterial diseases such as rice bacterial leaf blight.
|
| Enzyme Assay |
Non-cellular enzyme assays for Ipflufenoquin involve measuring DHODH enzymatic activity in the presence of varying concentrations of the compound. The enzyme is incubated with its substrate (dihydroorotate) and the coenzyme (ubiquinone or an analog), and the production of orotate is monitored spectrophotometrically. The IC50 value is determined by plotting enzyme activity against compound concentration. These assays confirm the compound's mechanism of action as a DHODH inhibitor.
|
| Cell Assay |
In vitro cellular assays for Ipflufenoquin are conducted using fungal cultures grown in liquid media. Mycelial growth inhibition is measured by culturing fungi in the presence of serial dilutions of the compound and measuring radial growth or biomass accumulation. Spore germination assays are also performed to assess the compound's ability to prevent fungal spore germination. EC50 values are calculated from dose-response curves to determine the compound's antifungal potency against various fungal species.
|
| Animal Protocol |
In vivo efficacy of Ipflufenoquin is evaluated in greenhouse and field trials on various crops. Plants are inoculated with pathogenic fungi and then treated with the compound at different concentrations and application timings. Disease severity is scored using standardized rating scales, and percent disease control is calculated relative to untreated controls. The compound's performance is compared to commercial fungicide standards to assess its relative efficacy and potential for resistance management.
|
| ADME/Pharmacokinetics |
Physicochemical properties of Ipflufenoquin include a molecular formula of C19H16F3NO2 and a molecular weight of 347.33. Its water solubility is 9.20×10⁻³ g/L at 20°C in pure water and 1.03×10⁻² g/L at pH 7. The log Pow is 3.89 at 25°C. The melting point ranges from 114.4 to 115.5°C, and the vapor pressure is <1.0×10⁻⁵ Pa at 20°C. The IUPAC name is 2-[2-[(7,8-difluoro-2-methylquinolin-3-yl)oxy]-6-fluorophenyl]propan-2-ol.
|
| Toxicity/Toxicokinetics |
Standard toxicological assessments for Ipflufenoquin would include acute oral, dermal, and inhalation toxicity studies in rodents, as well as sub-chronic and chronic toxicity studies. As an agricultural fungicide, its toxicity profile is evaluated according to regulatory requirements for pesticide registration. The compound would also undergo ecotoxicological testing to assess its impact on non-target organisms. Researchers should consult the safety data sheet for specific hazard information.
|
| References | |
| Additional Infomation |
Iflufenoquine is a quinoline compound with a structure in which the quinoline ring is substituted by methyl, 3-fluoro-2-(2-hydroxypropyl-2-yl)phenoxy, fluorine, and fluorine atoms at positions 2, 3, 7, and 8, respectively. It is a fungicide developed by Nippon-Soda Co., Ltd., and exhibits stable control effects against various plant diseases, such as gray mold, scab, and rice blast. Iflufenoquine belongs to the quinoline class, organofluorine compounds, aromatic ethers, and benzyl alcohol class.
Ipflufenoquin is marketed under the trade name イプフルフェノキン in Japan. It is not yet marketed in China. The compound has a novel mechanism of action and is considered a valuable tool for resistance management in agricultural settings. It is effective against a wide range of fungal pathogens affecting various crops. The compound may also have potential as a plant antiviral agent. |
| Molecular Formula |
C19H16F3NO2
|
|---|---|
| Molecular Weight |
347.33
|
| Exact Mass |
347.113
|
| CAS # |
1314008-27-9
|
| PubChem CID |
68289416
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
464
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(CO)=C(F)C=C(C)C(C)=C1OC1C=C2C(=NC=1C)C(F)=C(F)C=C2
|
| InChi Key |
DSXOWZNZGWXWMX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H16F3NO2/c1-10-15(9-11-7-8-13(21)17(22)18(11)23-10)25-14-6-4-5-12(20)16(14)19(2,3)24/h4-9,24H,1-3H3
|
| Chemical Name |
2-[2-(7,8-difluoro-2-methylquinolin-3-yl)oxy-6-fluorophenyl]propan-2-ol
|
| Synonyms |
ipflufenoquin; 1314008-27-9; Ipflufenoquin [ISO]; PU326EY34D; 2-(2-((7,8-Difluoro-2-methyl-3-quinolyl)oxy)-6-fluorophenyl)propan-2-ol;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~287.91 mM; with sonication (<80°C))
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (14.40 mM) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 50.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300 and mix well. Then add 50 μL Tween-80 to the above system and mix well. Then continue to add 450 μL of physiological saline to make up to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (14.40 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one),clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 50.0 mg/mL clear DMSO stock solution and add it to 900 μL corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8791 mL | 14.3955 mL | 28.7911 mL | |
| 5 mM | 0.5758 mL | 2.8791 mL | 5.7582 mL | |
| 10 mM | 0.2879 mL | 1.4396 mL | 2.8791 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
